

## **Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1%**

*Ahmedabad, India, 26 April, 2024*

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to market Tretinoin Cream USP, 0.1%, (USRLD: Retin-A Cream, 0.1%).

Tretinoin cream is used to treat acne. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India).

Tretinoin Cream USP, 0.1% had annual sales of USD 54.8 mn in the United States (IQVIA MAT Feb-24).

The group now has 394 approvals and has so far filed over 460\* ANDAs since the commencement of the filing process in FY 2003-04.

*(\*as of 31<sup>st</sup> December 2023)*

\*\*\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878